Previous 10 | Next 10 |
Image source: The Motley Fool. Reata Pharmaceuticals, Inc. (NASDAQ: RETA) Q2 2020 Earnings Call Aug 10, 2020 , 8:30 a.m. ET Operator Continue reading
Reata Pharmaceuticals, Inc. (RETA) Q2 2020 Earnings Conference Call August 10, 2020 8:30 am ET Corporate Participants Vineet Jindal - VP, Corporate Communications & Strategy Warren Huff - President and Chief Executive Officer Colin Meyer - Chief Research and Development Offic...
Gainers: Seres Therapeutics (NASDAQ: MCRB ) +356% . More news on: Seres Therapeutics, Inc., Xtant Medical Holdings, Inc., BiomX Inc., Stocks on the move, , Read more ...
Shares of Reata Pharmaceuticals (NASDAQ: RETA) were down by about 32% as of 12:21 p.m. EDT on Monday after the company released its second-quarter earnings report before the market opened. The financial results weren't the big story, however: In the update, the company said that its regulato...
Despite Q2 beat , Reata Pharmaceuticals (NASDAQ: RETA ) slumps 32% premarket on the heels of an update on Omaveloxolone for Friedreich’s Ataxia (FA) . More news on: Reata Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the...
Reata Pharmaceuticals (NASDAQ: RETA ) : Q2 Non-GAAP EPS of -$1.23; GAAP EPS of -$2.03 beats by $0.89 . More news on: Reata Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
PRE-NDA (NEW DRUG APPLICATION) MEETING GRANTED FOR BARDOXOLONE REGULATORY UPDATE ON OMAVELOXOLONE YEAR 2 DATA FROM CARDINAL TRIAL EXPECTED IN FOURTH QUARTER 2020 ENROLLMENT RESUMED IN FALCON TRIAL PLANO, Texas, Aug. 10, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceutical...
PLANO, Texas, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on ...
PLANO, Texas, July 30, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced the appointment of Martin W. Edwards, M.D. to its Board of Dire...
PLANO, Texas, July 28, 2020 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata,” the “Company,” or “we”), a clinical-stage biopharmaceutical company, today announced that researchers at NYU Grossman School of Medicine (“NY...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023